Johnson & Johnson $JNJ Shares Sold by Gradient Investments LLC

Posted by Francis Steltz on Oct 8th, 2026

Gradient Investments LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 21.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 119,405 shares of the company’s stock after selling 33,426 shares during the quarter. Gradient Investments LLC’s holdings in Johnson & Johnson were worth $31,611,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Avidian Wealth Enterprises LLC lifted its stake in Johnson & Johnson by 1.4% in the 3rd quarter. Avidian Wealth Enterprises LLC now owns 38,519 shares of the company’s stock valued at $10,198,000 after buying an additional 515 shares in the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Johnson & Johnson by 0.6% in the third quarter. Valeo Financial Advisors LLC now owns 62,954 shares of the company’s stock valued at $16,666,000 after acquiring an additional 380 shares in the last quarter. Veracity Capital LLC increased its position in Johnson & Johnson by 8.7% during the 3rd quarter. Veracity Capital LLC now owns 3,303 shares of the company’s stock worth $875,000 after purchasing an additional 264 shares in the last quarter. Vista Investment Partners LLC increased its position in Johnson & Johnson by 0.9% during the 3rd quarter. Vista Investment Partners LLC now owns 8,849 shares of the company’s stock worth $2,343,000 after purchasing an additional 83 shares in the last quarter. Finally, Plan A Wealth LLC raised its stake in Johnson & Johnson by 495.7% in the 3rd quarter. Plan A Wealth LLC now owns 16,036 shares of the company’s stock valued at $4,246,000 after purchasing an additional 13,344 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on JNJ. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 29th. Citigroup boosted their price target on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a report on Monday. Scotiabank reissued an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Finally, Johnson Rice reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $276.22.

Read Our Latest Report on JNJ

Johnson & Johnson Trading Down 1.2%

Shares of JNJ stock traded down $3.16 on Thursday, reaching $255.29. 2,654,376 shares of the stock were exchanged, compared to its average volume of 7,953,149. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The stock has a market cap of $615.21 billion, a P/E ratio of 29.61, a price-to-earnings-growth ratio of 2.50 and a beta of 0.21. The firm has a 50 day moving average of $265.71 and a two-hundred day moving average of $248.78. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson’s payout ratio is 62.11%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 87,569 shares of company stock valued at $23,064,544 in the last ninety days. Corporate insiders own 0.16% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Investor attention is focused on JNJ’s upcoming third-quarter report. Zacks says the company has a strong history of earnings surprises and currently shows conditions that could support another beat. Its previous quarter exceeded consensus on both earnings and revenue, while full-year 2026 guidance was raised. Zacks earnings surprise article
Positive Sentiment: Analysts remain supportive: Guggenheim reaffirmed a Buy rating with a $287 price target, and RBC Capital Markets maintained its Buy view. RBC cited accelerating Innovative Medicine sales as helping offset weakness in MedTech. RBC Capital rating article
Positive Sentiment: JNJ reported encouraging Phase 3 results for the Tecvayli-Talvey combination in relapsed or refractory multiple myeloma, including substantial reductions in the relative risks of disease progression and death. The data could support broader use of the company’s oncology portfolio. Cancer treatment advances article
Positive Sentiment: Two-year psoriasis data for oral ICOTYDE showed sustained skin clearance and consistent safety, strengthening the case for the medicine as a potential growth driver in difficult-to-treat psoriasis.
Neutral Sentiment: Articles continue to highlight JNJ’s 64-year dividend-growth record and premium valuation versus Pfizer, framing the company as a lower-yield but potentially more reliable income investment. Pfizer and Johnson & Johnson dividend comparison
Negative Sentiment: Near-term pressure may reflect risks investors are weighing before earnings, including biosimilar competition, slower MedTech growth and ongoing talc litigation. These concerns could limit valuation expansion even if pharmaceutical sales remain strong. Johnson & Johnson dividend and risk analysis

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.